UPDATE: Rigel Pharma Announces R343 Did Not Meet Primary, Secondary Endpoints in Asthma Trial

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study. The primary endpoint was the change in pre-bronchodilator FEV1 (a measure of lung